Skip to Content

Clinical Trial News

This section provides information about recently completed clinical trials. If you cannot find information about a particular clinical trial, you should note that results may not be available even after the trial ends. Some trials end before completion and results are never published.

Regeneron Announces Positive Topline Results from Phase 3 Trial of Evinacumab in Patients with Severe, Inherited Form of High Cholesterol

TARRYTOWN, N.Y., Aug. 14, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. today announced positive pivotal Phase 3 results for evinacumab, an... Read more...

Clinical Trials 3 days ago

Deciphera Pharmaceuticals Reports Positive Updated Phase 1 Data for Ripretinib in Gastrointestinal Stromal Tumors

WALTHAM, Mass.--(BUSINESS WIRE)--Aug. 13, 2019-- Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on... Read more...

Clinical Trials 5 days ago

Windtree Announces FDA Fast Track Designation for Istaroxime

WARRINGTON, Pa., Aug. 13, 2019 /PRNewswire/ -- Windtree Therapeutics, Inc. (OTCQB: WINT), a biotechnology and medical device company focused on developing drug... Read more...

Clinical Trials 5 days ago

PALM Ebola Clinical Trial Stopped Early as Regeneron's REGN-EB3 Therapy Shows Superiority to ZMapp in Preventing Ebola Deaths

TARRYTOWN, N.Y., Aug. 12, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the Company was informed by study... Read more...

Clinical Trials 6 days ago

Oncologie, Inc. Announces Clinical Trial Collaboration With Merck to Evaluate Bavituximab in Combination With Keytruda® (Pembrolizumab) in Advanced Gastric or Gastroesophageal Cancer

WALTHAM, Mass., Aug. 12, 2019 — Oncologie, Inc., a clinical-stage biopharmaceutical company developing innovative oncology treatments targeting the tumor m... Read more...

Clinical Trials 6 days ago

GSK Grants Exclusive Technology License for Clinical-Stage Ebola Vaccines to Sabin Vaccine Institute

London/Washington, D.C. 06 August 2019 -- GSK and the Sabin Vaccine Institute (Sabin) today announced exclusive agreements for Sabin to advance the development... Read more...

Clinical Trials 11 days ago

FDA Statement on Data Accuracy Issues with Recently Approved Gene Therapy

Statement From: Director - Center for Biologics Evaluation and Research (CBER) - Dr. Peter Marks M.D. PhD. August 06, 2019 -- As a public health agency, we... Read more...

Clinical Trials 12 days ago

Astellas Initiates Phase 3 Clinical Trials for Fezolinetant in Postmenopausal Women with Vasomotor Symptoms

TOKYO, Aug. 6, 2019 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced dosing of the first... Read more...

Clinical Trials 12 days ago

Pfizer Announces Phase 3 Top-Line Results for Rivipansel in Patients with Sickle Cell Disease Experiencing a Vaso-Occlusive Crisis

August 2, 2019 -- Pfizer Inc. (NYSE:PFE) announced today that the Phase 3 Rivipansel (GMI-1070): Evaluating Safety, Efficacy and Time to Discharge (RESET)... Read more...

Clinical Trials 2 weeks ago

Nektar Therapeutics and Bristol-Myers Squibb Announce U.S. FDA Breakthrough Therapy Designation for Bempegaldesleukin (NKTR-214) in Combination with Opdivo® (nivolumab) for the Treatment of Patients with Untreated Advanced Melanoma

August 01, 2019 -- Nektar Therapeutics (Nasdaq: NKTR) and Bristol-Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has... Read more...

Clinical Trials 2 weeks ago

Biohaven Enrolls First Patient In Phase 3 Clinical Trial Of Verdiperstat, Oral Myeloperoxidase Inhibitor, For The Treatment Of Multiple System Atrophy

NEW HAVEN, Conn., July 31, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) ("Biohaven" or the "Company"), a clinical stage... Read more...

Clinical Trials 2 weeks ago

Aclaris Therapeutics Announces Phase 2 Clinical Trial of ATI-501 Oral in Patients with Alopecia Areata Met Primary Endpoint

WAYNE, Pa., July 30, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on... Read more...

Clinical Trials 2 weeks ago

Diroximel Fumarate Demonstrated Significantly Improved Gastrointestinal Tolerability Profile Compared to Dimethyl Fumarate in Patients with Multiple Sclerosis

DUBLIN, Ireland and CAMBRIDGE, Mass., July 30, 2019 (GLOBE NEWSWIRE) -- Alkermes plc (Nasdaq: ALKS) and Biogen Inc. (Nasdaq: BIIB) today announced positive... Read more...

Clinical Trials 2 weeks ago

Janssen Reports Positive Top-Line Phase 3 results for Ponesimod in Adults with Relapsing Multiple Sclerosis

TITUSVILLE, NJ, July 25, 2019 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced positive top-line results from the Phase 3 OPTIMUM s... Read more...

Clinical Trials 3 weeks ago

La Jolla Pharmaceutical Company Receives Orphan Designation from FDA for LJPC-0118 (Artesunate) for the Treatment of Malaria

SAN DIEGO, CA – July 23, 2019 – La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative the... Read more...

Clinical Trials 3 weeks ago

FibroGen Announces First Patient Dosed in ZEPHYRUS, a Phase 3 Clinical Trial of Pamrevlumab for the Treatment of Patients with Idiopathic Pulmonary Fibrosis

SAN FRANCISCO, July 22, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), today announced dosing of the first patient in the ZEPHYRUS Phase 3 clinical... Read more...

Clinical Trials 3 weeks ago

Merck Presents Early Evidence on Extended Delivery of Investigational Anti-HIV-1 Agent Islatravir (MK-8591) via Subdermal Implant

KENILWORTH, N.J.--(BUSINESS WIRE) July 23, 2019 --Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today results from a Phase 1... Read more...

Clinical Trials 3 weeks ago

ViiV Healthcare Presents Positive 96-week Data from Phase III Study of Investigational Fostemsavir in Heavily Treatment-Experienced Patients with HIV at IAS 2019

London, UK, 22 July 2019 – ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, t... Read more...

Clinical Trials 3 weeks ago

Gilead Presents Proof-of-Concept Data for GS-6207, a First-in-Class Capsid Inhibitor, in People Living With HIV

FOSTER CITY, Calif.--(BUSINESS WIRE)--Jul. 22, 2019-- Gilead Sciences, Inc. (NASDAQ: GILD) today presented the first clinical data in people living with HIV on... Read more...

Clinical Trials 3 weeks ago

Orphazyme to Prepare for Filing of Arimoclomol in US for Niemann-Pick Disease Type C (NPC)

Copenhagen, July 21, 2019 – Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare d... Read more...

Clinical Trials 3 weeks ago
View older articles

More News Resources

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.